News & Updates
Filter by Specialty:
SGLT2i beats DPP4i at reducing cardiovascular disease in type 2 diabetes
Treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2i) leads to lower rates of cardiovascular disease (CVD) events in patients with type 2 diabetes mellitus (T2DM) than does dipeptidyl peptidase-4 inhibitors (DPP4i), reports a recent Japan study.
SGLT2i beats DPP4i at reducing cardiovascular disease in type 2 diabetes
18 May 2022
Adults with nephrotic syndrome at greater risk of thromboembolism, bleeding
The risk of arterial thromboembolism, venous thromboembolism, and bleeding is higher in adults with nephrotic syndrome than the general population, a study has found. However, the mechanisms and consequences of this association warrant further research.
Adults with nephrotic syndrome at greater risk of thromboembolism, bleeding
17 May 2022
Modern radiotherapy safe for heart in breast cancer patients
Breast cancer patients see no excess risk of ischaemic heart disease (IHD)-related mortality after radiotherapy (RT) treatment, according to a recent Singapore study.
Modern radiotherapy safe for heart in breast cancer patients
17 May 2022
Beta-blockers reduce mortality risk in older patients with HFrEF
Use of beta-blockers results in a lower risk of all-cause mortality, but not of heart failure (HF) readmission, in older patients with HR with reduced ejection fraction (HFrEF), reports a recent study. Results are similar between patients admitted and not admitted from nursing homes.